Literature DB >> 10608346

Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects.

C C Heise1, A Williams, J Olesch, D H Kirn.   

Abstract

ONYX-015 is an E1B-deleted adenovirus that replicates in and causes lysis of p53-deficient cancer cells selectively. To study the efficiency of intratumoral (i.t.) spread by ONYX-015, we infected specific fractions of tumor cells (two p53-deficient tumor lines and one p53 functional line) in vitro before subcutaneous inoculation into nude mice. Infection of as few as 5% of p53- tumor cells prevented tumor development in all cases; infection of 1% of p53- tumor cells resulted in significant growth inhibition but did not prevent tumor formation. In contrast, infection with ONYX-015 had no significant effect on p53+ tumor formation. These data suggested that replication-dependent tumor cell lysis and spread was occurring, but that tumor destruction might be improved by increasing i.t. virus distribution. Two treatment parameters were then varied to determine whether virus distribution, and consequently efficacy, could be improved. Divided i.t. injections of virus were more efficacious than a single injection of the same total dose. Likewise, increasing the volume of the viral suspension for i.t. injection allowed better distribution within the tumor mass and increased efficacy. These results have implications for the treatment of cancer patients with viral agents.

Entities:  

Mesh:

Year:  1999        PMID: 10608346     DOI: 10.1038/sj.cgt.7700071

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  27 in total

Review 1.  Replication-selective adenoviruses as oncolytic agents.

Authors:  C Heise; D H Kirn
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 2.  Prodrug-activating systems in suicide gene therapy.

Authors:  C J Springer; I Niculescu-Duvaz
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 3.  Immunomodulation of cancer: potential use of selectively replicating agents.

Authors:  S Agha-Mohammadi; M T Lotze
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 4.  Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

Authors:  B R Dix; S J Edwards; A W Braithwaite
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 5.  Crossing the boundaries: stem cells and gene therapy.

Authors:  Sherise D Ferguson; Atique U Ahmed; Bart Thaci; Ronald W Mercer; Maciej S Lesniak
Journal:  Discov Med       Date:  2010-03       Impact factor: 2.970

Review 6.  Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region.

Authors:  Amanda Psyrri; George Fountzilas
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

7.  Sustained, localized transgene expression mediated from lentivirus-loaded biodegradable polyester elastomers.

Authors:  Michele C Jen; Kevin Baler; Ashleigh R Hood; Seungjin Shin; Lonnie D Shea; Guillermo A Ameer
Journal:  J Biomed Mater Res A       Date:  2012-10-15       Impact factor: 4.396

8.  A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.

Authors:  John Nemunaitis; Alex W Tong; Michael Nemunaitis; Neil Senzer; Anagha P Phadke; Cynthia Bedell; Ned Adams; Yu-An Zhang; Phillip B Maples; Salina Chen; Beena Pappen; James Burke; Daiju Ichimaru; Yasuo Urata; Toshiyoshi Fujiwara
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

Review 9.  ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.

Authors:  S Ries; W M Korn
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

10.  Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5.

Authors:  J-L Hsieh; C-L Wu; M-D Lai; C-H Lee; C-S Tsai; A-L Shiau
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.